Danaher Corp to Acquire Masimo for $9.9 Billion
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 17 2026
0mins
Source: stocktwits
Danaher Corp's stock rose by 3.00% as it reached a 20-day high amid broader market declines.
The company is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion, with completion expected in the second half of 2026. This acquisition will allow Masimo to operate as a standalone business within Danaher's Diagnostics segment, reflecting ongoing consolidation in the healthcare sector.
This acquisition positions Danaher for future growth and strengthens its portfolio in diagnostics, despite the overall market weakness reflected in the Nasdaq-100 and S&P 500.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 188.410
Low
240.00
Averages
266.18
High
310.00
Current: 188.410
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Acquisition Impact: Danaher Corp. is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion including debt, with completion expected in the second half of 2026, allowing Masimo to operate as a standalone business within Danaher's Diagnostics segment.
- Index Change: S&P Dow Jones Indices announced that Sirius XM will replace Masimo in the S&P MidCap 400 effective June 11, which is anticipated to trigger buying from index-tracking funds and ETFs, further enhancing Sirius XM's market performance.
- Market Reaction: Sirius XM's market capitalization is around $9 billion, and its shares rose 5% in after-hours trading on Monday, reflecting positive market sentiment regarding its inclusion in the mid-cap index, despite retail investor sentiment remaining bearish.
- Year-to-Date Performance: Sirius XM's stock has gained 34% this year, driven by Berkshire Hathaway's increasing stake and a significant audio advertising partnership with YouTube, indicating the company's ongoing growth potential in the audio entertainment sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings will replace Masimo Corp. in the S&P MidCap 400 Index effective June 11, 2026, which is expected to enhance Sirius XM's visibility in the capital markets and boost investor confidence.
- Acquisition Dynamics: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, which may impact Masimo's market performance and its standing in the healthcare sector.
- Market Impact: Adjustments to the S&P MidCap 400 Index typically prompt investors to reassess their positions, and Sirius XM's inclusion may attract more capital inflow, potentially enhancing its stock performance.
- Industry Outlook: As the largest index provider globally, changes by S&P Dow Jones Indices reflect market confidence in a company's future growth potential, and Sirius XM's inclusion signifies further recognition in the communication services sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings Inc. will replace Masimo Corp. in the S&P MidCap 400 effective June 11, 2026, enhancing Sirius XM's market visibility and investment appeal.
- Acquisition Context: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, leading to Masimo's deletion from the MidCap 400, reflecting ongoing market consolidation in the healthcare sector.
- Market Impact: The inclusion of Sirius XM may attract more investor attention, particularly in the communication services sector, potentially driving up its stock price and strengthening its competitive position.
- Industry Trends: This change not only highlights S&P Dow Jones Indices' responsiveness to market dynamics but also underscores the significance of mid-cap companies in the capital markets, possibly motivating other firms to aim for similar index inclusion.
See More
SiriusXM to Replace Masimo in S&P MidCap 400 Index
- Index Component Change: SiriusXM Holdings (SIRI) will replace Masimo (MASI) in the S&P MidCap 400 Index prior to market open, enhancing SiriusXM's market visibility and liquidity, potentially attracting more investor interest.
- Market Impact Analysis: As part of the mid-cap index, SiriusXM's inclusion is expected to increase its trading volume, which may drive up its stock price, reflecting market confidence in its future growth potential.
- Investor Attention Boost: Changes in S&P MidCap 400 Index components typically garner significant investor attention, and SiriusXM's replacement may prompt fund managers to reassess their portfolios, thereby increasing investment in the company.
- Strategic Significance: This replacement not only signifies an elevation of SiriusXM's market position but may also provide more opportunities for future capital operations and business expansion, further solidifying its leadership in the audio entertainment industry.
See More
SCHG ETF 52-Week Price Analysis
- Price Range Analysis: SCHG ETF's 52-week low is $27.685 per share, with a high of $35.42, and a current trading price of $35.10, indicating stability near its high point, which may attract investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities, thereby optimizing investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, reflecting changes in market interest for the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can impact the ETF's underlying holdings and overall performance.
See More
Valuation Analysis of U.S. Healthcare Stocks
- High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
- Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
- Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
- Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Acquisition Impact: Danaher Corp. is set to acquire Masimo for $180 per share, valuing the deal at approximately $9.9 billion including debt, with completion expected in the second half of 2026, allowing Masimo to operate as a standalone business within Danaher's Diagnostics segment.
- Index Change: S&P Dow Jones Indices announced that Sirius XM will replace Masimo in the S&P MidCap 400 effective June 11, which is anticipated to trigger buying from index-tracking funds and ETFs, further enhancing Sirius XM's market performance.
- Market Reaction: Sirius XM's market capitalization is around $9 billion, and its shares rose 5% in after-hours trading on Monday, reflecting positive market sentiment regarding its inclusion in the mid-cap index, despite retail investor sentiment remaining bearish.
- Year-to-Date Performance: Sirius XM's stock has gained 34% this year, driven by Berkshire Hathaway's increasing stake and a significant audio advertising partnership with YouTube, indicating the company's ongoing growth potential in the audio entertainment sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings will replace Masimo Corp. in the S&P MidCap 400 Index effective June 11, 2026, which is expected to enhance Sirius XM's visibility in the capital markets and boost investor confidence.
- Acquisition Dynamics: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, which may impact Masimo's market performance and its standing in the healthcare sector.
- Market Impact: Adjustments to the S&P MidCap 400 Index typically prompt investors to reassess their positions, and Sirius XM's inclusion may attract more capital inflow, potentially enhancing its stock performance.
- Industry Outlook: As the largest index provider globally, changes by S&P Dow Jones Indices reflect market confidence in a company's future growth potential, and Sirius XM's inclusion signifies further recognition in the communication services sector.
See More
Sirius XM to Replace Masimo in S&P MidCap 400 Index
- Index Change: Sirius XM Holdings Inc. will replace Masimo Corp. in the S&P MidCap 400 effective June 11, 2026, enhancing Sirius XM's market visibility and investment appeal.
- Acquisition Context: Danaher Corp. is acquiring Masimo, with the deal expected to close soon, leading to Masimo's deletion from the MidCap 400, reflecting ongoing market consolidation in the healthcare sector.
- Market Impact: The inclusion of Sirius XM may attract more investor attention, particularly in the communication services sector, potentially driving up its stock price and strengthening its competitive position.
- Industry Trends: This change not only highlights S&P Dow Jones Indices' responsiveness to market dynamics but also underscores the significance of mid-cap companies in the capital markets, possibly motivating other firms to aim for similar index inclusion.
See More
SiriusXM to Replace Masimo in S&P MidCap 400 Index
- Index Component Change: SiriusXM Holdings (SIRI) will replace Masimo (MASI) in the S&P MidCap 400 Index prior to market open, enhancing SiriusXM's market visibility and liquidity, potentially attracting more investor interest.
- Market Impact Analysis: As part of the mid-cap index, SiriusXM's inclusion is expected to increase its trading volume, which may drive up its stock price, reflecting market confidence in its future growth potential.
- Investor Attention Boost: Changes in S&P MidCap 400 Index components typically garner significant investor attention, and SiriusXM's replacement may prompt fund managers to reassess their portfolios, thereby increasing investment in the company.
- Strategic Significance: This replacement not only signifies an elevation of SiriusXM's market position but may also provide more opportunities for future capital operations and business expansion, further solidifying its leadership in the audio entertainment industry.
See More
SCHG ETF 52-Week Price Analysis
- Price Range Analysis: SCHG ETF's 52-week low is $27.685 per share, with a high of $35.42, and a current trading price of $35.10, indicating stability near its high point, which may attract investor interest in price fluctuations.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping to assess market trends and potential buying opportunities, thereby optimizing investment decisions.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors are buying and selling 'units' that can be created or destroyed based on investor demand, reflecting changes in market interest for the fund.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows (new units created) or outflows (old units destroyed), which can impact the ETF's underlying holdings and overall performance.
See More
Valuation Analysis of U.S. Healthcare Stocks
- High Valuation Companies: Among U.S. healthcare stocks with market caps over $10 billion, Agilent Technologies (A) stands out with a valuation grade of F, indicating its high valuation relative to peers, which may influence investor purchasing decisions.
- Valuation Scoring Mechanism: Seeking Alpha's valuation grades assess stocks based on a comprehensive set of metrics including P/E, PEG, and EV/Sales, providing crucial insights for investors regarding relative pricing within the sector.
- Other High Valuation Stocks: Companies like Danaher Corporation (DHR) and GE HealthCare Technologies (GEHC) also received an F valuation grade, highlighting the high valuation risks these firms face in the current market environment, prompting investors to reassess their portfolios.
- Market Dynamics: Despite Summit Therapeutics (SMMT) facing downward pressure following recent clinical data releases, the overall valuation landscape for healthcare stocks indicates a cautious investor sentiment towards high valuation stocks, potentially affecting future capital flows.
See More
